Table 5.

Toxicity from CCRT between the two arms. Table 5 showed the incidence of acute adverse events by type and grade from CCRT. There were no significantly statistical differences in the hematologic, RT-related mucositis and dermatitis between two arms.

Adverse events	Nimotuzumab					Non-nimotuzumab					Z	P
	0	1	2	3	4	0	1	2	3	4
Hematologic
Leukopenia	43	46	23	8	0	44	40	24	12	0	-0.373	0.709
Neutropenia	37	42	26	13	2	39	41	27	10	3	-0.281	0.779
Anemia	100	14	6	0	0	96	19	5	0	0	-0.603	0.547
Thrombocytopenia	92	13	8	7	0	96	15	6	3	0	-0.783	0.433
Liver function	108	10	2	0	0	112	8	0	0	0	-0.963	0.336
Renal function	104	6	0	0	0	106	4	0	0	0	-0.646	0.518
Non-hematologic
Mucositis	0	43	63	12	2	0	47	58	14	1	-0.373	0.709
Dermatitis	0	103	12	5	0	0	99	18	3	0	-0.625	0.532
Diarrhea	108	7	4	1	0	109	8	3	0	0	-0.259	0.796
Nausea/vomiting	102	16	2	0	0	103	12	4	1	0	-0.094	0.925

Abbreviations: CCRT concurrent chemoradiotherapy.